Stem Cell Educator therapy, an experimental procedure, passes a person's own white blood cells over donor cord blood stem cells and returns them, aiming to retrain an immune system that attacks the body's own tissues. One small type 1 diabetes study suggests better blood glucose control; other results lack comparison groups, and healthy ageing is untested. Short-term risks appear modest; nearly all evidence comes from the inventor. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting C-peptide | 0.3–3.3 ng/mL | Own insulin output |
| Stimulated C-peptide | Not specified in the ER | Own insulin output |
| HbA1c | Below 7% | 3-month glucose average |
| CGM time in range (70–180 mg/dL) | Above 70% | Daily glucose control |
| CGM time below 70 mg/dL | Below 4% | Hypoglycemia as insulin needs fall |
| Daily insulin dose | Not specified in the ER | Changing insulin needs |
| Regulatory T cells (CD4⁺CD25⁺FOXP3⁺) | No established target; track change from own baseline | Proposed immune mechanism |
| Platelet count | 150–400 × 10⁹/L | Apheresis blood-cell loss |
| HLA antibody screen (transplant candidates) | Not specified in the ER | Donor sensitization |
Cadence: Baseline panel before the session; then at 4, 12, 24 and 40 weeks after it, then every 6–12 months. Continuous glucose monitoring throughout the first 12 weeks; platelets before and 24 hours after the session.